Premium
14 C‐labelling of a novel antiischaemic adenosine A 1 agonist at purine C‐8
Author(s) -
Valsborg Jacob S.,
Knutsen Lars J. S.,
Foged Christian
Publication year - 1996
Publication title -
journal of labelled compounds and radiopharmaceuticals
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.432
H-Index - 47
eISSN - 1099-1344
pISSN - 0362-4803
DOI - 10.1002/(sici)1099-1344(199605)38:5<497::aid-jlcr855>3.0.co;2-b
Subject(s) - chemistry , adenosine , labelling , agonist , yield (engineering) , purine , thio , radiochemistry , specific activity , medicinal chemistry , stereochemistry , organic chemistry , biochemistry , receptor , enzyme , materials science , metallurgy
A 14 C‐labelled form of 2‐chloro‐ N ‐[(R)‐(2‐benzoxazolyl)thio‐2‐propyl]adenosine ( 1 ), a novel antiischaemic adenosine A 1 agonist, has been prepared in three steps from [8‐ 14 C]‐9‐(2,3,5‐tri‐ O ‐benzoyl‐β‐D‐ribofuranosyl)‐2,6‐dichloropurine ( 2 ). The overall radiochemical yield was 56%. The radiochemical purity was higher than 98% with a specific radioactivity of 36 mCi/mmol.